Revelation Biosciences, Inc. (REVB)
NASDAQ: REVB · Real-Time Price · USD
2.600
-0.030 (-1.14%)
At close: Apr 1, 2025, 4:00 PM
2.500
-0.100 (-3.85%)
After-hours: Apr 1, 2025, 4:16 PM EDT
Company Description
Revelation Biosciences, Inc. operates as a clinical-stage biopharmaceutical company that focuses on the development and commercialization of immune system therapeutics and diagnostics.
It engages in developing therapeutic product candidates, including GEM-AKI, a potential therapy for the prevention and treatment of acute kidney injury; and GEM-CKD, a potential therapy for the prevention and treatment of chronic kidney disease.
The company was formerly known as Petra Acquisition, Inc. and changed its name to Revelation Biosciences, Inc. in January 2022.
Revelation Biosciences, Inc. was incorporated in 2019 and is based in San Diego, California.
Revelation Biosciences, Inc.
| Country | United States |
| Founded | 2020 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 9 |
| CEO | James Rolke |
Contact Details
Address: 4660 La Jolla Village Drive, Suite 100 San Diego, California 92122 United States | |
| Phone | (650) 800-3717 |
| Website | revbiosciences.com |
Stock Details
| Ticker Symbol | REVB |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001810560 |
| CUSIP Number | 76135L101 |
| ISIN Number | US76135L5075 |
| Employer ID | 84-3898466 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| James M. Rolke | Chief Executive Officer and Director |
| Chester Stanley Zygmont III | Chief Financial Officer and Corporate Secretary |
| Sandra Vedrick | Vice President of Human Resources and Investor Relations |
| Carol Odle | Senior Director of Clinical Projects |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Mar 17, 2025 | 8-K | Current Report |
| Mar 6, 2025 | 8-K | Current Report |
| Mar 6, 2025 | 10-K | Annual Report |
| Feb 24, 2025 | 8-K | Current Report |
| Feb 11, 2025 | 8-K | Current Report |
| Jan 30, 2025 | 8-K | Current Report |
| Jan 21, 2025 | 8-K | Current Report |
| Jan 13, 2025 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Jan 7, 2025 | 8-K | Current Report |
| Jan 2, 2025 | SCHEDULE 13G/A | Filing |